{"entity":{"id":"nct05970016","kind":"trial","name":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.","aka":[],"tldr":"A phase 1/2 trial of TCC1727 tablet（1） in advanced solid tumours, run by Beijing Tide Pharmaceutical Co., Ltd, now recruiting.","summary":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. is a phase 1/2 interventional study registered as NCT05970016 by Beijing Tide Pharmaceutical Co., Ltd, with 56 participants planned, started 2023-08-07 and due to reach its primary completion in 2025-07-30. Interventions recorded: TCC1727 tablet（1） and TCC1727 tablet（2）.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05970016","url":"https://clinicaltrials.gov/study/NCT05970016"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05970016","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TCC1727 Tablets in Patients with Advanced Solid Tumor.","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","enrolled":56,"outcomes":[]},"route":"/trials/nct05970016/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/"}]}}